Company intelligence / Profile preview

Miluda

New York, New York, United States of Americamiluda.com ↗

Ownership: Private
Employees: ~9
Development stage: Other

Overview

Milu Labs is developing two innovative diagnostic platforms to address unmet needs in women's health across Asia. One leverages exosomes for predictive risk analysis; the other integrates multiomics data using artificial intelligence to provide actionable clinical insights. The company collaborates with global academic institutions and American healthcare companies to advance these technologies. No published clinical results as of the latest available information

Therapeutic areas: Women's Health
Modalities: Diagnostic platform (Exosome-based)Diagnostic platform (Multiomics, including proteome, transcriptome, epigenome, microbiome analysis)
Industry: Molecular Diagnostics

Partnerships

Collaborations with global academic institutions and top American healthcare companies are mentioned but not specified by name

Beyond the preview

Go deeper on Miluda.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Miluda.

Explore the full profile